10-13 November 2022 Budapest
![]() |
![]() |
![]() |
![]() |
P-002 | Simultaneous bilateral video-assisted inguinal lymphadenectomy: The best solution? | José Pereira | ![]() |
![]() |
|||
O-002 | Does metastases-direct therapy guided by PSMA PET/CT really improve oncologic outcomes in oligorecurrent prostate cancer patients? | Alessandro Pissavini | ![]() |
![]() |
|||
P-003 | Risk of local recurrence in men with Penile Intraepithelial Neoplasia (PeIN) in the surgical margin after penile sparing surgery | Christian Fankhauser | ![]() |
![]() |
|||
O-003 | Prognosis of primary papillary Ta-G3 bladder cancer in the non-muscle invasive spectrum | Irene Beijert | ![]() |
![]() |
|||
O-006 | Risk of residual teratoma after complete response following first-line chemotherapy in men with metastatic non-seminomatous germ cell tumor and IGCCCG intermediate/poor prognosis: A multi-institutional retrospective cohort study | Christian Fankhauser | ![]() |
![]() |
|||
P-013 | Immunohistochemical PSMA expression and histology predictors in primary staging high-risk prostate cancer patients studied with PSMA PET/CT | Alessandro Pissavini | ![]() |
![]() |
|||
P-019 | Characterization of significant prostate cancer invisible and visible in imaging tests | Morillo Tejedor Ana Cristina | ![]() |
![]() |
|||
P-025 | Description of Castration-Resistant Prostate Cancer with Unknown Metastatic Status (CRPC-MX) population in the real-world AfrODiTA study | Alba Quesada-García | ![]() |
![]() |
|||
P-027 | Avoiding false-positive MRI results in prostate cancer-suspected men: A step forward towards reducing overdiagnosis | Mar Fernandez Salamanca | ![]() |
![]() |
|||
P-029 | Comparative study between micro-ultrasonography-guided biopsy (EXACTVUTM) and multiparametric MRI-guided biopsy (KOELISTM system) for prostate cancer diagnosis | Esther García Rojo | ![]() |
![]() |
|||
P-033 | Genomic classifiers in personalized prostate cancer radiotherapy approaches a systematic review and future perspectives based on international consensus | Simon Spohn | ![]() |
![]() |
|||
P-035 | Is cribriform pattern in biopsy a risk factor for metastatic disease on 68Ga-PSMA-PET/CT? | Joris Heetman | ![]() |
![]() |
|||
P-039 | Analysis of the evolution of a real world practice prostate cancer cohort on active surveillance | Juan Luis Sanz Miguelañez | ![]() |
![]() |
|||
P-041 | Use of BioProtect balloon in patients with low- or intermediate-risk prostate cancer receiving dose-escalated EBRT: A retrospective, single institution study reporting rectal spacing and dosimetry | Paulo Costa | ![]() |
![]() |
|||
P-042 | Location-based oncological outcomes of sentinel node dissection during radical prostatectomy: Are all sentinel nodes equal? | Alessandro Pissavini | ![]() |
![]() |
|||
P-044 | Clinical impact of ERG and PTEN alterations in men underwent radical prostatectomy | Panagiotis Velissarios Stamatakos | ![]() |
![]() |
|||
P-050 | Wait-and-see protocol in patients with biochemical recurrence after robot-assisted radical prostatectomy, with no evidence of disease on restaging PSMA PET/CT | Katelijne de Bie | ![]() |
![]() |
|||
P-052 | Genetic variants at 8q24 region are associated with prostate cancer susceptibility in a Southeastern European population | Panagiotis Vlachostergios | ![]() |
![]() |
|||
P-054 | Preliminary results from SIESTA, a pilot observational study investigating sleep quality in prostate cancer patients | Fabio Turco | ![]() |
![]() |
|||
P-055 | Correlation of claims based and patient reported pad use for incontinence one year after radical prostatectomy | Diederik Baas | ![]() |
![]() |
|||
P-058 | Long term durable effect of PectaSol-C Modified Citrus Pectin (P-MCP) treatment (tx) in non- metastatic Biochemically Relapsed Prostate Cancer (BRPC-M0) patients (pts): Results of a prospective Phase II Study | Daniel Keizman | ![]() |
![]() |
|||
P-059 | Radical prostatectomy versus high-dose-rate brachytherapy and hypo-fractionated external beam radiation combined with long-term androgen deprivation for high-risk prostate cancer | Keiichiro Mori | ![]() |
![]() |
|||
P-064 | Retrospective observational study to assess the treatment pathway and patient journey among men who undergo radiotherapy for high-risk localised and locally advanced prostate cancer in Sweden: ODYSSEY | Megan Berger | ![]() |
![]() |
|||
P-069 | Identification of clinically significant recurrence patterns in biochemical recurrence after radical prostatectomy and first salvage treatment in patients with prostate cancer using Ga68 PSMA PET-CT | Guillermo Barbas Bernardos | ![]() |
![]() |
|||
P-070 | Pattern of local recurrence after radical prostatectomy diagnosed on PSMA PET/CT | Floor Staal | ![]() |
![]() |
|||
P-072 | A prospective, multicenter head-to-head comparative study in patients with primary high-risk prostate cancer investigating the diagnostic performance of conventional imaging and 18F-PSMA-PET/CT | Wietske Luining | ![]() |
![]() |
|||
P-074 | Analysis of the frequency of occurrence of mutations in repair genes in patients with prostate cancer in the Republic of Bashkortostan | Alexnder Sultanbaev | ![]() |
![]() |
|||
P-075 | Local recurrence after salvage post prostatectomy radiotherapy, from palliative to potentially curative? | Guillermo Barbas Bernardos | ![]() |
![]() |
|||
P-079 | Analysis of PSA response to apalutamide in metastatic castration sensitive prostate cancer | Juan Luis Sanz Miguelañez | ![]() |
![]() |
|||
P-080 | Testosterone recovery for relugolix vs. leuprolide in men with advanced prostate cancer: Results from the phase 3 HERO study | THIERRY SCHULMANN | ![]() |
![]() |
|||
P-081 | Oral relugolix for androgen deprivation therapy in advanced prostate cancer: Detailed safety analysis from the randomized phase 3 HERO study | THIERRY SCHULMANN | ![]() |
![]() |
|||
P-085 | Rash in patients treated with apalutamide in different prostate cancer settings. A real world study | Carmen Munoz Calahorro | ![]() |
![]() |
|||
P-091 | The impact of PSMA PET/CT on oncologic outcomes of patients with recurrent prostate cancer: The experience of 3 high-volume European centers | Alessandro Pissavini | ![]() |
![]() |
|||
P-096 | Prognostic factors in the use of immune checkpoint inhibitors for metastatic renal cell carcinoma | Hirotaka Nagasaka | ![]() |
![]() |
|||
P-099 | Tivozanib as first line treatment for metastatic renal cell carcinoma | luis cajal | ![]() |
![]() |
|||
P-101 | 3D models for surgery planning in renal cell carcinoma with venous thrombus extension. Phase II nct03738488: Predictibility | Inés Rivero Belenchón | ![]() |
![]() |
|||
P-102 | The role of cytoreductive nephrectomy in the era of immune-combination therapies: A meta-analysis | Keiichiro Mori | ![]() |
![]() |
|||
P-103 | Re-treatment with immune checkpoint inhibitors in renal cell carcinoma: A systematic review and meta-analysis | Panagiotis Vlachostergios | ![]() |
![]() |
|||
P-104 | The impact of 3D modeling in surgical planning and outcomes of partial nephrectomy | Alessandro Pissavini | ![]() |
![]() |
|||
P-105 | 3D virtual models for planning percutaneous Cryoablation of small renal masses | Alessandro Pissavini | ![]() |
![]() |
|||
P-106 | PERC-score as a nephrometry scoring system in percutaneous tumour ablation: Comparison with RENAL, mRENAL, PADUA and SPARE in a multi-centre series | Alessandro Pissavini | ![]() |
![]() |
|||
P-110 | Impact of the COVID-19 pandemic on kidney cancer care in the Netherlands | Hilin Yildirim | ![]() |
![]() |
|||
P-113 | Impact of subsequent therapies in patients (pts) with advanced renal cell carcinoma (aRCC) receiving lenvatinib plus pembrolizumab (LENPEMBRO) or sunitinib (SUN) in the CLEAR study | Laura Hendrickson | ![]() |
![]() |
|||
P-114 | Hereditary renal cell carcinoma surveillance protocols - a review and new surveillance protocol proposal | Miguel Miranda | ![]() |
![]() |
|||
P-118 | The impact of histology and type of energy used on oncological outcomes after local tumor ablation of small renal masses | Alessandro Pissavini | ![]() |
![]() |
|||
P-123 | Treatment outcomes of men with stage 2 non-seminomatous germ cell tumours treated with primary retroperitoneal lymph node dissection: A systematic review | Christian Fankhauser | ![]() |
![]() |
|||
P-124 | IMvigor010: Updated analysis of Overall Survival (OS) by circulating tumour DNA (ctDNA) status in patients with post-operative Muscle-Invasive Urothelial Carcinoma (MIUC) treated with atezolizumab | Christina ReyesWright | ![]() |
![]() |
|||
P-125 | ATM loss and therapeutic vulnerabilities in bladder cancer | Kent Mouw | ![]() |
![]() |
|||
P-131 | DNA mismatch repair testing in upper tract urothelial carcinoma patients - Is Universal Lynch Syndrome screening necessary? | Orlane Figaroa | ![]() |
![]() |
|||
P-132 | Evaluation of a cytology-molecular co-test in urine of patients with non-muscle invasive urothelial cancer | Panagiotis Vlachostergios | ![]() |
![]() |
|||
P-133 | Bladder cancer detection in urine using DNA methylation markers: A prospective preclinical validation | Irene Beijert | ![]() |
![]() |
|||
P-139 | Results of phase I dose escalation of the trifunctional anti-EpCAM/CD3 bsAb Catumaxomab in intravesical therapy of high risk non muscle invasive bladder cancer (HR-NMIBC): Excellent tolerability and encouraging preliminary efficacy | Guenter Fingerle-Rowson | ![]() |
![]() |
|||
P-149 | Avelumab as maintenance treatment in advanced urothelial cancer in the Portuguese population: A multicentric registry analysis | Joao Gramaa | ![]() |
![]() |
|||
P-150 | Role of neutrophil-to-lymphocytes ratio in predicting non-complete response at 3 months evaluation after BCG induction in non-muscle invasive bladder cancer | Daehyuk Chung | ![]() |
![]() |
|||
P-151 | Follow-up after kidney sparing surgery in upper tract urothelial carcinoma, an overview of 10 year contemporary data; Do we need to adjust current follow up protocol? | Orlane Figaroa | ![]() |
![]() |
|||
P-152 | Prognostic value of vascular endothelial growth factor and vascular cell adhesion molecule-1 in bladder carcinoma | Keiichiro Mori | ![]() |
![]() |
|||
P-160 | Urostoma APPtimize: Improving quality of life of patients having an urostomy by offering personalised and timed guidance in a patient-centred mobile application | Noor van Ginkel | ![]() |
![]() |
|||
P-162 | COVID-19 pandemic impact in bladder cancer treatment and features | José Pereira | ![]() |
![]() |
|||
P-163 | Practical approach and surgical outcome to treatment rectourinary fistula in male cancer patients | Liliya Tryfonyuk | ![]() |
![]() |
|||
LB-166 | VOLGA: Results from the phase 3 safety run-in with durvalumab (D) tremelimumab (T) enfertumab vedotin (EV) fer cisplatin-ineligible muscle-invasive bladder cancer (MIBC) | Thomas Powles | ![]() |
![]() |
10-13 November 2022 Budapest
![]() |
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. ![]() To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress. ![]() |
![]() |
||
![]() |
|